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Background: Idiopathic Parkinson’s disease is marked by degeneration of dopamine neurons projecting from the
substantia nigra to the striatum. Although proteins expressed by the target striatum can positively affect the
viability and growth of dopaminergic neurons, very little is known about the molecular response of the striatum as
nigro-striatal denervation progresses. Here, iTRAQ labelling and MALDI TOF/TOF mass spectrometry have been used
to quantitatively compare the striatal proteome of rats before, during, and after 6-OHDA induced dopamine
denervation.
Results: iTRAQ analysis revealed the differential expression of 50 proteins at 3 days, 26 proteins at 7 days, and 34
proteins at 14 days post-lesioning, compared to the unlesioned striatum. While the denervated striatum showed a
reduced expression of proteins associated with the loss of dopaminergic input (e.g., TH and DARPP-32), there was an
increased expression of proteins associated with regeneration and growth of neurites (e.g., GFAP). In particular, the
expression of guanine deaminase (GDA, cypin) – a protein known to be involved in dendritic branching – was
significantly increased in the striatum at 3, 7 and 14 days post-lesioning (a finding verified by immunohistochemistry).
Conclusions: Together, these findings provide evidence to suggest that the response of the normal mammalian
striatum to nigro-striatal denervation includes the increased expression of proteins that may have the capacity to
facilitate repair and growth of neuronal circuitry.
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Idiopathic Parkinson’s disease (PD) affects approximately
1-2% of the world’s over-60 population [1-4], making it
the second most common neurodegenerative disorder
after Alzheimer’s disease. The hallmark of Parkinson’s
disease is progressive degeneration of dopamine neurons
that project from the substantia nigra pars compacta
(SNc) to the striatum (i.e., the nigro-striatal circuit) [5].
Over the past decade, great strides have been made to-
wards detailing the abnormal molecular make up of SNc* Correspondence: m.a.gates@keele.ac.uk
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unless otherwise stated.dopamine neurons, and the altered physiological proper-
ties of dopamine neurons that may contribute to their
degeneration in the adult brain [6-8]. However, very little
is known about the protein expression of cells in the
striatum (the target of nigro-striatal dopamine neurons)
during SNc degeneration. This is unfortunate due to the
fact that immature SNc dopamine neurons depend on
molecules produced by the striatum to grow appropri-
ately during development, and rely on trophic support
from proteins produced in the striatum to maintain their
viability during and after development [9-14].
The present study was designed to use the animal
model of Parkinson’s disease (i.e., the 6-OHDA medial
forebrain bundle lesioned rat) to unveil how thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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response to active degeneration of the nigro-striatal cir-
cuit. Here, relative levels of proteins expressed in the
adult rat striatum as nigro-striatal denervation pro-
gresses have been detailed using iTRAQ labelling and
MALDI TOF/TOF mass spectrometry. Quantitatively
comparing the proteome of the target striatum before,
during and after dopamine deafferentation has: (1) de-
tailed the degradation of the dopaminergic afferents
from the striatum; (2) highlighted a potential remedial
response by glial cells in the striatum; and (3) revealed
potential remedial responses in the striatum that could
be directed at facilitating repair and / or viability of the
nigro-striatal system. Because the 6-OHDA model of PD
conveys (in the absence of other developmental events)
what proteins the otherwise healthy adult striatum ex-
presses when the survival and connectivity of nigro-
striatal neurons is compromised, this has offered the
unique opportunity to: unveil a proteome that may be
tailored to SNc neuron viability, growth, and/or connect-
ivity; and identify proteins whose expression may occur
merely as a response to nigro-striatal degeneration itself
(and, therefore, not be part of the aetiology of Parkin-
son’s disease).
Results
The unilateral, medial forebrain bundle 6-OHDA lesion
rat model of Parkinson’s disease was used to determine
the relative levels of proteins expressed in the adult rat
striatum before, during (3 days), and after (7 and 14 days)
6-OHDA induced dopamine denervation. Animals that
were unlesioned (control), or 3 days, 7 days, or 14 days
post 6-OHDA injection (lesioning), were either perfusedFigure 1 A schematic diagram illustrating medial forebrain bundle le
innervation. A sagittal section from a non-lesioned rat brain, stained with
cells residing in the substantia nigra pars compacta (SNc) extend long axon
innervating the striatum (Str). For lesioning, a small glass capillary (vertical a
SNc and Str (i.e., along the medial forebrain bundle). The 6-OHDA was slow
degeneration of SNc dopamine neurons and their axonal innervation of thwith ice cold paraformaldehyde for histology studies
(group 1: n = 4) or ice-cold sterile 0.9% sodium chloride
(saline) for proteomic and western blot analysis (group
2: n = 4). A photomicrograph illustrating the location of
the striatum to the unilateral medial forebrain bundle le-
sion and substantia nigra dopamine neurons is shown in
Figure 1.
To verify and illustrate the level of deafferentation of
the striatum from its dopaminergic input, we performed
histological staining of coronal sections through unle-
sioned and 6-OHDA lesioned brains from animals pre-
pared solely for histology analyses (group 1) using an
antibody to tyrosine hydroxylase (Figure 2).
While TH staining in the unlesioned brain showed
high levels of diffuse TH immunofluorescence through-
out the striatum (Figure 2A), staining at 3 days post
lesioning showed only sparse staining of TH + varicose
fibers in the striatal grey matter (Figure 2B). By the 7th
day post lesioning there were no detectable TH + fibers
within the striatal grey matter, indicating a complete de-
afferentation of the striatum from its nigral input by the
end of the first week post 6-OHDA lesioning (Figure 2C).
As expected, there was no change in the absence of TH
staining in the striatum at 14 days post-lesioning, with
the entire striatum continuing to be void of TH immu-
noreactivity (Figure 2D). This time course of loss of
dopaminergic input to the striatum matched well the
trend seen with western blot analysis of protein ex-
tracted from a second group of lesioned animals that
were prepared specifically for proteomics and western
blot analyses (group 2) (Figure 2E).
In order to determine which striatal proteins are chan-
ged in expression as the nuclei loses its nigral input, wesioning used to detach the striatum from dopaminergic
an antibody to tyrosine hydroxylase (TH), highlights how dopaminergic
al fibers through the medial forebrain bundle on their way to
rrow) was filled with 6-OHDA and lowered to a point between the
ly injected (black dot with halo surrounding) to produce a gradual
e striatum. Rostral is left, dorsal is up. Scale bar = 2 mm.
Figure 2 Tyrosine hydroxylase (TH) immunoreactivity decreases by 3 days post-lesioning and is undetectable after 7 and 14 days
post-lesioning. Tyrosine hydroxylase (TH) immunoreactivity in coronal sections through the striatum of (A) unlesioned), (B) 3 day, (C) 7 day, and
(D) 14 day post-lesioned animals, highlights the ongoing loss of dopaminergic input to the striatum at time points used for proteomic analysis.
Though there is a noticeable staining of numerous TH + process in the striatum of the unlesioned brain (A), only few swollen, varicose TH +
process remain in the striatum at 3 days post 6-OHDA lesioning (arrow in B). As expected, there was no detectable staining of TH in the striatum
after 7 days post lesioning (C), and this remained unchanged at 14 days (D) post 6-OHDA injection to the medial forebrain bundle. Scale bars in
A-D = 10 μm. Striatal protein extracts were subjected to SDS-PAGE and transferred to nitrocellulose by electroblotting blotting (E). The blot was
probed with an antibody against tyrosine hydroxylase – TH, with beta III tubulin as an internal loading control. PL = post 6-OHDA lesioning.
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liquid chromatography and MALDI TOF/TOF mass spec-
trometry analysis using total protein extracted from the
striatum of animals in group two at 3 days, 7 days, 14 days
post-6-OHDA lesion and an unlesioned control. Using
this approach to simultaneously compare the proteome of
the unlesioned striatum, with the striatal proteome during
nigro-striatal degeneration, a total of 1009 proteins were
detected (with the stringent search settings, described in
the materials and methods section; Additional file 1: Table
S1 and Additional file 2: Table S2). To enable reliable
quantification and robust statistical analysis of the dataset,
proteins identified by fewer than 3 peptides were rejected,
even though some proteins that are genuinely altered inexpression may be excluded in this way. Small and low
abundance proteins are more difficult to detect and if
identified, are more likely to be represented by fewer
peptides than larger and more abundant proteins. An
example of this is tyrosine hydroxylase (TH) (hit 943,
Additional file 2: Table S2), which was detected with
just one peptide (despite the fact that the iTRAQ ratios
of the peptide indicated substantial down-regulation at
3 days, 7 days and 14 days post-lesion, compared to the
unlesioned sample), and was subsequently filtered from
the dataset. The raw iTRAQ data have therefore been
provided as supplementary tables to enable researchers
to analyse the data as they wish, or to select other pro-
tein targets for further study.
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using less than 3 peptides, 480 proteins remained in the
data set. To establish which proteins were differentially
expressed after lesioning, a +/− 1.25x fold change cut off
was applied to the remaining 480 proteins. This level of
(lesser or greater) fold change was chosen as it can be
more easily validated using other biochemical / im-
munological methods such as quantitative western blot-
ting [15]. This left 99 proteins at 3 days, 62 proteins at
7 days and 77 proteins at 14 days post-lesion, compared
to the control unlesioned animals. Finally, statistical sig-
nificance of the difference between individual peptide
iTRAQ ratios for the remaining post-lesion and unle-
sioned proteins was determined using a Student’s one-
tailed, pairwise t-test. Proteins that were significantly dif-
ferent in their expression levels (i.e., either up or down
regulated) in the striatum among unlesioned and experi-
mental groups (i.e. those with a p-value of less than
0.05) totaled 50 proteins at 3 days post-lesioning
(Table 1), 26 proteins at 7 days post–lesioning (Table 2),
and 34 proteins at 14 days post–lesioning (Table 3).
To gain some insight into the molecular functions of
the differentially expressed proteins, the filtered lists of
differentially expressed proteins (Tables 1, 2 and 3) were
analysed using Ingenuity Pathway Analysis software
(IPA). Functional annotations that were assigned with a
p value >0.05 and with fewer than three proteins were
removed from the list. To highlight annotations that
may reflect changes in neuronal connectivity following
deafferentation from its nigral input, we further filtered
the list to include only those that contained the follow-
ing keywords in the annotation: axon, dendrite, den-
dritic, synapse, synaptic and neurite.
Several of the proteins that were up-regulated at 3 and
7 days post-lesion (almost 20% at 7 days) were assigned
to the term “regeneration of neurites”, which is of poten-
tial interest when considering the healing, survival,
growth of cells in the CNS (Figure 3). The most substan-
tially increased protein in this category was glial fibrillary
acidic protein (GFAP). GFAP “reactivity” among astro-
cytes is a widely accepted marker of a wound-healing re-
sponse in the central nervous system [16]. To verify that
GFAP was not increased because of a global wound-
healing response to anesthetic and craniotomy, we com-
pared GFAP expression levels in the non-lesioned side
of the striatum from animals that had undergone 6-
OHDA lesioning with animals that had not been sub-
jected to operative procedures. Histological staining of
coronal sections through the striatum of animals pre-
pared for histology (group 1) confirmed that there was
no significant difference in GFAP expression levels in
the non-lesioned side of the 6-OHDA lesioned animals
compared to those which had not been subjected to op-
erative procedures (Figure 4). In both cases, sparse levelsof GFAP expression were observed, with a majority of
the immunopositive cells being perivascular astrocytes.
Furthermore, a comparison of GFAP expression levels in
the lesisoned and non-lesioned side of each 6-OHDA le-
sioned animal revealed a significant increase in GFAP
expression in the lesioned side only. Intense GFAP + re-
activity could be seen in astrocytes throughout the le-
sioned side of the striatum, with glial cells showing
swollen GFAP + soma and processes. Although most evi-
dent during active nigro-striatal degeneration (i.e. at
3 days post-lesion), increased GFAP reactivity was still
obvious at 7 and 14 days post-lesion, even though
complete deafferentation of the striatum from its nigral
input had been established for several days (Figure 2).
The substantial increase in GFAP expression at 3 days
post-lesioning (compared to the non-operated, control
striatum), and a lessening of this reactivity in the subse-
quent 1–2 weeks matched the iTRAQ quantification
trend well (Tables 1, 2 and 3), and was further confirmed
by western blot analysis of the striatum taken from the
second group of lesioned animals (group 2) (Figure 5A).
Over one fifth (22%) of the up-regulated proteins iden-
tified at 3 days post-lesion were assigned to the term
“growth of neurites”. Among this category were neurofil-
ament (NF) heavy and medium polypeptides (which
were increased in comparison to controls by 1.98 x and
1.90 x, at 3 days post-lesioning respectively; Table 1).
This was followed by a reduction of neurofilament heavy
polypeptide to 0.73 x, compared to the control, by
14 days post lesioning (Table 3). This trend of increased
neurofilament expression during ongoing nigro-striatal
degeneration, followed by a reduction in its expression
in the fully denervated striatum was verified by western
blotting (Figure 5B). Interestingly, despite the western
blot indictating a reduced expression of NF levels at
7 days post-lesioning (compared to the control), other
proteins associated with “growth of neurites” were in-
creased at this time point (Figure 3).
Strikingly, all of the functional annotations that were
assigned to the down-regulated proteins identified at
3 days post-lesion were related to the synapse (e.g. “synap-
tic transmission” and “synaptic plasticity”), even though
the more general marker of the terminal end of axons,
GAP43, showed little or no change in expression before,
during and after nigro-striatal degeneration (Figure 5C) in
western blotting. Proteins whose expression was down-
regulated include synaptophysin, synGAP, NipSnap and
homer 1 (Table 1). Interestingly, by 7 days post-lesioning
(when deafferentation of the striatum becomes complete),
this general trend of reduced expression of synaptic pro-
teins appears to be reversed (Figure 3), when an increase
in proteins related to “synaptic transmission” becomes evi-
dent. This increase is maintained at 14 days post-
lesioning. An exception to this trend is the decrease in
Table 1 Differentially expressed proteins at 3 days post-lesioning
Protein name Average iTRAQ ratio (3 days post-lesion/unlesioned) p value
Down-regulated
Diacylglycerol kinase beta [9506535] 0.57 +/− 0.2 [4] 0.0192
Synaptophysin [6981622] 0.59 +/− 0.18 [5] 0.0035
Synaptic ras GTPase-activating protein p135 SynGAP [2935448] 0.62 +/− 0.1 [7] 2.92E-05
Ras-related protein Rab-3C [19424194] 0.67 +/− 0.13 [5] 0.0029
Protein NipSnap homolog 2 [62945328] 0.67 +/− 0.06 [3] 0.0066
Prohibitin [6679299] 0.67 +/− 0.26 [6] 0.0069
Succinyl-CoA synthetase alpha subunit [204356] 0.69 +/− 0.26 [5] 0.0486
RII-B-binding protein [557585] 0.69 +/− 0.12 [4] 0.0074
Type II cAMP-dependent protein kinase regulatory subunit [206671] 0.70 +/− 0.14 [16] 3.45E-08
A-kinase anchor protein 5 [19424156] 0.71 +/− 0.22 [5] 0.0276
RNA binding protein p37 AUF1 [9588102] 0.71 +/− 0.3 [6] 0.0325
Erythrocyte adducin subunit beta [10720378] 0.72 +/− 0.12 [6] 0.0010
Septin-5 [90577179] 0.72 +/− 0.09 [7] 0.0001
Reticulon-3 isoform A [57977297] 0.72 +/− 0.18 [5] 0.0151
Homer protein homolog 1 [13928988] 0.73 +/− 0.26 [6] 0.0484
Ras-related protein Rab-3C [13470090] 0.74 +/− 0.15 [5] 0.0093
V-type proton ATPase 116 kDa subunit a isoform 1 [139352] 0.75 +/− 0.22 [8] 0.0107
Up-regulated
Tenascin-R precursor [6981668] 1.25 +/− 0.64 [8] 0.0545
Cytoplasmic dynein 1 light intermediate chain 1 [21955134] 1.25 +/− 0.12 [3] 0.0409
Rap1b [595280] 1.25 +/− 0.08 [4] 0.0048
G protein beta 1 subunit [984553] 1.27 +/− 0.36 [7] 0.0373
6-phosphofructokinase, muscle type [13929002] 1.27 +/− 0.47 [8] 0.0482
Transketolase [12018252] 1.27 +/− 0.32 [6] 0.0429
Guanine deaminase [148747414] 1.30 +/− 0.8 [14] 0.0453
Band 4.1-like protein 3 [16758808] 1.31 +/− 0.51 [10] 0.0145
Similar to 14-3-3 protein sigma [51260816] 1.34 +/− 0.3 [5] 0.0378
Eukaryotic initiation factor 4A-I isoform 1 [4503529] 1.34 +/− 0.25 [4] 0.0425
Reticulon-4 [13929188] 1.36 +/− 0.26 [6] 0.0080
Dihydropyrimidinase-related protein 4 [3122037] 1.38 +/− 0.35 [7] 0.0117
cGMP-dependent 3',5'-cyclic phosphodiesterase isoform 2 [13592021] 1.45 +/− 0.64 [6] 0.0544
Glutathione S-transferase P [25453420] 1.48 +/− 0.18 [4] 0.0067
Cytosol aminopeptidase [58865398] 1.53 +/− 0.4 [5] 0.0166
Glycyl-tRNA synthetase; [81889021] 1.54 +/− 0.24 [3] 0.0353
Chondroitin sulfate proteoglycan core protein 2 [21431624] 1.61 +/− 0.66 [4] 0.0585
Platelet-activating factor acetylhydrolase IB subunit alpha [7305363] 1.77 +/− 0.4 [3] 0.0409
NAD-dependent deacetylase sirtuin-2 [56605812] 1.78 +/− 0.51 [9] 0.0005
Carbonic anhydrase 2 [9506445] 1.79 +/− 0.54 [6] 0.0049
Myelin-oligodendrocyte glycoprotein precursor [158262022] 1.85 +/− 0.2 [5] 0.0005
Myelin proteolipid protein [13591880] 1.85 +/− 0.62 [17] 5.15E-06
Myelin basic protein [4454317] 1.86 +/− 0.59 [14] 1.84E-05
PMES-2C [55700833] 1.87 +/− 0.62 [4] 0.0307
Alpha-internexin [9506811] 1.87 +/− 0.54 [18] 1.5E-07
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Table 1 Differentially expressed proteins at 3 days post-lesioning (Continued)
NF-M protein [205688] 1.90 +/− 0.53 [19] 8.36E-09
Myelin basic protein isoform 4 [70166270] 1.92 +/− 0.61 [15] 4.4E-06
Neurofilament light polypeptide [13929098] 1.92 +/− 0.64 [11] 4.56E-05
2',3'-cyclic-nucleotide 3'-phosphodiesterase [57977323] 1.92 +/− 0.59 [29] 5.17E-11
High molecular-weight neurofilament [2642598] 1.98 +/− 0.75 [8] 0.0006
Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic [57527919] 1.99 +/− 0.32 [3] 0.0216
Glial fibrillary acidic protein [158186732] 3.44 +/− 2.58 [8] 0.0118
Proteins altered at 3 days post-lesion after strict filtering of the raw data. The significance of the difference between the average iTRAQ ratios for each protein at
3 days post-lesion, compared to the unlesioned control was calculated by analysing peptide ratios (see Additional file 2: Table S2) using a one-tailed, Student’s
pairwise t-test. Only significant changes (i.e. those with p values of <0.05) are shown. Column headings refer to the following: protein name = given name in
NCBInr database, [NCBI accession number]; Average iTRAQ ratio (3 days post-lesion/unlesioned) = average iTRAQ after data normalisation, +/− standard deviation
from mean, [n] = number of peptides used for quantification.
Table 2 Differentially expressed proteins at 7 days post-lesioning
Protein name Average iTRAQ ratio(7 days post-lesion/unlesioned) p value
Down-regulated
Protein phosphatase 1 regulatory subunit 1B (DARPP32) [61889054] 0.60 +/− 0.37 [6] 0.0321
Complexin-2 [5729783] 0.62 +/− 0.13 [4] 0.0057
Adh5 protein [54035294] 0.64 +/− 0.14 [3] 0.0335
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [13489075] 0.71 +/− 0.30 [9] 0.0018
NADH dehydrogenase [ubiquinone] iron-sulfur protein 4 [68341995] 0.73 +/− 0.14 [3] 0.0507
Microsomal Cytochrome B5 [6980893] 0.74 +/− 0.06 [3] 0.0115
Neuron-specific calcium-binding protein hippocalcin [6754240] 0.74 +/− 0.18 [8] 0.0042
Up-regulated
Macrophage migration inhibitory factor [694108] 1.25 +/− 0.14 [3] 0.0537
Guanine nucleotide-binding protein G(z) subunit alpha [6980966] 1.27 +/− 0.10 [3] 0.0304
Clathrin-associated protein 17 [1809320] 1.30 +/− 0.14 [3] 0.0399
ApoE [202959] 1.32 +/− 0.20 [4] 0.0278
Brain acid soluble protein 1 [11560135] 1.33 +/− 0.71 [10] 0.0292
Gamma-enolase [26023949] 1.33 +/− 0.75 [16] 0.0165
Astrocytic phosphoprotein PEA-15 [4505705] 1.34 +/− 0.28 [4] 0.0481
Microtubule-associated protein RP/EB family member 3 [39930509] 1.39 +/− 0.65 [6] 0.0479
Platelet-activating factor acetylhydrolase IB subunit alpha [7305363] 1.39 +/− 0.09 [3] 0.0130
Beta-enolase [126723393] 1.40 +/− 0.96 [10] 0.0400
Synaptic vesicle glycoprotein 2B [17105360] 1.44 +/− 0.26 [6] 0.0042
Thiomorpholine-carboxylate dehydrogenase [16758840] 1.46 +/− 0.33 [4] 0.0312
Protein IMPACT [58866042] 1.49 +/− 0.12 [3] 0.0126
Sorting and assembly machinery component 50 homolog [51948454] 1.59 +/− 0.21 [3] 0.0233
Guanine deaminase [148747414] 1.59 +/− 1.04 [14] 0.0097
LanC-like protein 2 [62079109] 1.73 +/− 0.30 [4] 0.0094
Glial fibrillary acidic protein [158186732] 1.94 +/− 0.87 [8] 0.0047
Proteins altered at 7 days post-lesion after strict filtering of the raw data. The significance of the difference between the average iTRAQ ratios for each protein at
7 days post-lesion, compared to the unlesioned control was calculated by analysing peptide ratios (see Additional file 2: Table S2) using a one-tailed, Student’s
pairwise t-test. Only significant changes (i.e. those with p values of <0.05) are shown. Column headings refer to the following: protein name = given name in
NCBInr database, [NCBI accession number]; Average iTRAQ ratio (7 days post-lesion/unlesioned) = average iTRAQ after data normalisation, +/− standard deviation
from mean, [n] = number of peptides used for quantification.
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Table 3 Differentially expressed proteins at 14 days post-lesioning
Protein name Average iTRAQ ratio (14 days post-lesion/unlesioned) p value
Down-regulated
Importin subunit beta-1 [8393610] 0.59 +/− 0.37 [5] 0.0407
Complexin-2 [5729783] 0.59 +/− 0.16 [4] 0.0068
Annexin A6 [130502086] 0.61 +/− 0.37 [7] 0.0263
Myelin basic protein isoform 4 [70166270] 0.67 +/− 0.21 [15] 3.27E-06
Protein phosphatase 1 regulatory subunit 1B (DARPP32) [61889054] 0.67 +/− 0.15 [6] 0.0019
Myelin basic protein [4454317] 0.68 +/− 0.24 [14] 2.76E-05
Plasma membrane calcium-transporting ATPase 3 [158138481] 0.69 +/− 0.14 [6] 0.0018
Cystatin C [227013] 0.71 +/− 0.14 [3] 0.0522
High molecular-weight neurofilament [2642598] 0.73 +/− 0.27 [8] 0.0074
Myelin-oligodendrocyte glycoprotein precursor [158262022] 0.73 +/− 0.08 [5] 0.0011
Myelin proteolipid protein [13591880] 0.74 +/− 0.24 [17] 0.0001
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [13489075] 0.74 +/− 0.24 [9] 0.0039
3',5'-cyclic nucleotide phosphodiesterase 1B [12083681] 0.75 +/− 0.26 [9] 0.0091
Up-regulated
Mu Class Glutathione S-Transferase [442967] 1.25 +/− 0.22 [9] 0.0050
Chain A, Tetra-(5-Fluorotryptophanyl)-Glutathione Transferase [4388948] 1.25 +/− 0.22 [9] 0.0051
Chain A, Tetradeca-(3-Fluorotyrosyl)- Glutathione S-Transferase [5107744] 1.26 +/− 0.25 [7] 0.0182
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10-like [32996721] 1.27 +/− 0.16 [4] 0.0244
V-type proton ATPase subunit B, brain isoform [17105370] 1.27 +/− 0.39 [9] 0.0250
Voltage dependent anion channel [4105605] 1.27 +/− 0.42 [10] 0.0248
Hyaluronan and proteoglycan link protein 1 [1346731] 1.27 +/− 0.32 [6] 0.0402
RNA binding protein p37 AUF1 [9588102] 1.29 +/− 0.48 [6] 0.0565
Clathryn light chain (LCA2) [203276] 1.29 +/− 0.20 [4] 0.0336
Synapsin-1 isoform b [160707907] 1.29 +/− 0.43 [18] 0.0020
Neural cell adhesion molecule long domain form [281037] 1.31 +/− 0.48 [6] 0.0516
Glutathione S-transferase Yb-3 [13592152] 1.31 +/− 0.28 [7] 0.0116
Synapsin-2 isoform 1 [77404242] 1.33 +/− 0.30 [12] 0.0007
ADP-ribosylation factor 5 [4502209] 1.36 +/− 0.16 [3] 0.0359
Guanine deaminase [148747414] 1.40 +/− 0.83 [14] 0.0126
Glial fibrillary acidic protein [158186732] 1.53 +/− 1.00 [8] 0.0321
Thiomorpholine-carboxylate dehydrogenase [16758840] 1.53 +/− 0.49 [4] 0.0592
LanC-like protein 2 [62079109] 1.54 +/− 0.43 [4] 0.0406
Synaptic vesicle glycoprotein 2B [17105360] 1.56 +/− 0.44 [6] 0.0088
Sorting and assembly machinery component 50 homolog [51948454] 1.94 +/− 0.58 [3] 0.0524
Proteins altered at 14 days post-lesion after strict filtering of the raw data. The significance of the difference between the average iTRAQ ratios for each protein at
14 days post-lesion, compared to the unlesioned control was calculated by analysing peptide ratios (see Additional file 2: Table S2) using a one-tailed, Student’s
pairwise t-test. Only significant changes (i.e. those with p values of <0.05) are shown. Column headings refer to the following: protein name = given name in
NCBInr database, [NCBI accession number]; Average iTRAQ ratio (14 days post-lesion/unlesioned) = average iTRAQ after data normalisation, +/− standard deviation
from mean, [n] = number of peptides used for quantification.
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protein phosphatase 1, regulatory (inhibitor) subunit 1B
(DARPP-32) at 7- and 14 days post-lesion (Tables 2 and
3). DARPP-32 is a protein long known to be associated
with transmission at dopaminergic synapses, although its
precise function is not fully understood [17,18]. Thedecreased expression of DARPP-32, as suggested by the
iTRAQ data (Tables 2 and 3), was verified by western blot-
ting (Figure 6D).
The increased expression of guanine deaminase (GDA;
also known as cypin), at 3, 7 and 14 days post-lesion
(Tables 1, 2 and 3) is of particular interest due to its
Figure 3 A graph illustrating the functional annotations that were assigned to the filtered lists of differentially expressed proteins
using Ingenuity Pathway Analysis software (IPA).
Figure 4 Glial fibrillary acidic protein (GFAP) immunoreactivity is increased at 3, 7 and 14 days post-lesioning. Glial fibrillary acidic
protein (GFAP) immunoreactivity in coronal sections through the unlesioned and lesioned side of striatum from control (unlesioned), 3 days-,
7 days-, and 14 days-post-lesioned animals. At 3 days following 6-OHDA injection along the medial forebrain bundle, widespread and intense
GFAP immunoreactivity can be seen in astrocytes throughout the entire striatal complex. Though this level of astrocyte reactivity had subsided
somewhat by 7 days post lesioning, the level of GFAP expression in the striatum did not return to the levels seen in the unlesioned brain even
after 14 days post lesioning. Scale bar for figures = 10 μm.
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Figure 5 Western blotting verifies the expression levels of several proteins that were identified by iTRAQ analysis. Striatal protein
extracts were subjected to SDS-PAGE and transferred to nitrocellulose either by electroblotting blotting (B), or by diffusion blotting to produce
two identical blots from one gel (A, C, and D). Blots were probed with antibodies against (A) glial fibrillary acidic protein - GFAP, (B) neurofilament
heavy polypeptide - NFh, (C) growth associated protein 43 - GAP43, or (D) dopamine- or cAMP- regulated neuronal phosphoprotein - DARPP-32, with
beta III tubulin as an internal loading control in each case. PL = post 6-OHDA lesioning.
Figure 6 Guanine deaminase (GDA) is increased in the striatum at 7 and 14 days post-lesioning. Guanine deaminase (GDA)
immunoreactivity in coronal sections through the striatum of (A, E, and I) unlesioned, (B, F, and J) 3 day, (C, G, and K) 7 day, and (D, H, and L)
14 day post-lesioned animals. High power, confocal images of the (top row) dorsal, (middle row) medial, and (bottom row) ventral portions of
the striatum were taken to both see the fine staining by GDA immunoreactive fibers, and document the protein’s expression throughout the
striatum. Though fiber bundles (“striations”) of the striatum were highly reactive for GDA in control and lesioned brains (arrows in E), there was
only low levels of reactivity within the striatal grey matter of the unlesioned brain. Immunoreactivity for GDA in the brain 3 days post-lesioning
(B, F, and J) suggests some change in the protein’s expression in the grey matter, however, an increase in GDA immunoreactivity was not
notable until 7 days post 6-OHDA lesioning (C, G, and K). At this stage, and at 14 days post-lesioning (D, H, and L), numerous fibers, with long
thick processes (suggestive of dendrites) were stained throughout the dorsal, medial, and ventral grey matter of the entire striatum. Scale bars for
each figure are shown at the bottom right of each image.
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tation of dendritic branching [19,20]; a term also
enriched in the IPA analysis at 3 days post-lesioning. Al-
though the available anti-GDA antibody was not suitable
for detection of GDA by western blotting, the trend of
GDA expression in the striatum as deafferentation pro-
gressed was verified by immunohistochemical staining of
sections of the striatum taken from lesioned animals
processed for immunohistochemical analyses (group 1)
(Figure 6). High power confocal micrographs from dor-
sal, medial, and ventral segments of the striatum show
that while the white matter tracts of the striatum where
intensely stained in both control and lesioned animals,
there was a notable increase in staining intensity in fi-
brous processes in the grey matter of the striatum at
3 days. This increase in staining intensity was much
more pronounced in sections from the striatum after 7
and 14 days post-lesioning, with large networks of fi-
brous GDA + staining seen throughout much of the stri-
atal grey matter.
Discussion
Over the past two decades, there have been attempts to
take advantage of proteins (re)expressed by the striatum
to improve the survival and / or growth of endogenous
or transplanted SNc dopamine neurons. Studies in both
rat and primate models of PD, for example, have shown
that co-grafting embryonic striatal tissue (or cells) with
immature ventral mesencephalic (VM) cells significantly
increases the survival and growth of transplanted dopa-
mine neurons [11,21,22]. Perhaps more interestingly are
observations from the rodent model of PD showing that
the denervated adult striatum is itself capable of promot-
ing the growth of immature dopaminergic axons in vivo
[23]. Although such studies highlight the (therapeutic)
potential of both developmentally regulated and adult
striatal proteins to enhance the growth and viability of
nigro-striatal dopamine neurons, very little is known
about the proteome of the striatum in both the normal
and lesioned brain.
Here, the rodent model of Parkinson’s disease (i.e., 6-
OHDA lesioning of adult rats) has been used to identify
and quantify proteins expressed in the otherwise normal
mammalian striatum during ongoing detachment from
SNc dopaminergic neurons. Comparing the proteome of
the striatum before, during, and after dopamine denerv-
ation has detailed not only proteins related to the on-
going degeneration of nigro-striatal input, but also
potential regenerative responses by cells in the striatum
indicative of wound healing, and growth / plasticity. De-
tailing the proteome in this way has not only identified
the molecular response of the otherwise normal adult
brain to the challenge of preserving the viability and
connectivity of the nigro-striatal circuit, but also offers abase line for comparison (in future studies) with the Par-
kinsonian brain to determine if the target striatum in
humans responds similarly to this same challenge.
Changes in protein expression related to the
degeneration of nigro-striatal dopamine neurons
Immunohistochemistry for TH, revealed the loss of
dopaminergic input to the striatum at 3, 7, and 14 days
post 6-OHDA lesioning (Figures 1 and 2). Accompany-
ing this, iTRAQ analysis of the striatal proteome at
3 days post lesioning suggests that the expression of cer-
tain synaptic proteins (e.g., synaptophysin, synaptic ras
GTPase-activating protein) may also be affected by this
denervation (Table 1; Figure 3). Western blot analysis of
DARPP-32, a protein long known to be associated with
transmission at dopaminergic synapses [17,18] verified
iTRAQ analysis showing that when cells within the stri-
atum are completely detached from their nigro-striatal
input (i.e., at 7 and 14 days post 6-OHDA lesioning),
there is a corresponding reduction in dopamine synapse-
related proteins. These alterations in the proteome
might be expected when considering that as destruction
of afferent SNc dopamine neurons proceeds, there is a
concomitant loss of proteins related to dopaminergic
connectivity (i.e., synapses) within the striatum. Such
findings support previous assertions that nigro-striatal
denervation negatively affects DARPP-32 expression
[24], though this contrasts with other (indirect) estima-
tions suggesting that denervation may not affect striatal
DARPP-32 levels [25]. It will be important to clarify the
effect of dopamine denervation on DARPP-32 expres-
sion in the striatum of human PD sufferers, as inactiva-
tion of DARPP-32 in mice can significantly reduce the
possibility of l-dopa induced dyskinesias [26].
Interestingly, there appears to be a significant increase
in proteins associated with axonal reorganization (e.g.
neurofilament polypeptides) during ongoing dopamine
denervation of the striatum (i.e., at 3 days post lesioning;
Table 1 and Figure 3), followed by a reduction (in com-
parison to controls) after nigro-striatal degeneration is
complete at 7 and 14 days post 6-OHDA injection. This
seems confounding when considering there is a substan-
tial loss of dopaminergic fibres from the SNc at 3 days
post lesioning. An initial increase in cytoskeletal proteins
could represent either swelling of nigro-striatal axons
during anterior-grade degeneration (as seen with the
varicose TH staining at 3 days post lesioning, Figure 2),
or an up-regulation in the cytoskeleton of other intact
afferent axons (e.g., cortico-striatal axons). It’s unlikely
that this initial increase in cytoskeletal proteins is related
to swelling of degenerating nigro-striatal afferents at
3 days post lesioning, as there is a near complete loss of
dopaminergic fibers by this stage of degeneration. Be-
cause the expression profile of neurofilament proteins is
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duced at 14 days (in comparison to the intact striatum;
see Additional file 1: Table S1-Additional file 2: Table
S2, Table 3, and Figure 5B), this seems to indicate that if
initial increases in the cytoskeletal proteins in the stri-
atum is related to plasticity or new growth, then this is a
very rapid process. This seems possible when consider-
ing that the remaining striatal afferents (e.g., cortico-
striatal projections) will have synapses on the same cells
that have lost their dopaminergic afferent input.
Changes in proteins related to growth and regeneration
of neurites
The possibility that there is a heightened period of plas-
ticity / wound healing / regeneration in the striatum is
supported by IPA bioinformatics analysis which indicates
that several proteins found to be up-regulated in re-
sponse to lesioning (e.g., neural cell adhesion molecule
NCAM; Table 3) are categorised by “regeneration of
neurites”. In fact, the response of cells in the striatum to
the loss of dopaminergic input appears to be very similar
to that seen with wound healing after traumatic injury
[16]. This response is important to clarify as such pro-
teins in the adult brain can have a dramatic effect on cell
survival and the potential for neurons (including trans-
planted cells) to regenerate into a site where these pro-
teins are expressed [27]. Though the striatum receives
no direct physical trauma during 6-OHDA lesioning of
the medial forebrain bundle (Figure 1), astrocytes be-
come highly reactive by 3 days post lesioning, increasing
their level of GFAP expression at a time when dopamine
denervation is ongoing (Figure 4). This reactivity in the
striatum subsides somewhat by the 7th day post lesioning
(when dopamine denervation is complete), but levels of
GFAP expression remain higher than that seen in the in-
tact striatum. This astrocyte reactivity appears to be ac-
companied by an increase in the expression of other
astrocyte-related proteins (e.g., tenascin, CSPG, and hya-
luronan; Tables 1, 2 and 3) that are known to be associ-
ated with wound healing in the brain [16]. Such proteins
are commonly expressed as part of the extracellular
matrix that helps stabilise perineuronal nets [28], and fa-
cilitate cell and neurite adhesion [29,30]. Because astro-
cytes are known to play a major role in buffering the
environment of neuronal cells (including; modulating
the presence of neurotransmitters and potassium, pro-
viding a reservoir of glycogen for increased neuronal ac-
tivity, and the potential to perform the dual role of
helping in the formation and elimination of synapses)
[31], it will be important to determine their level of re-
sponse in Parkinson’s disease. It may well be that astro-
cytes can provide a means by which the viability of
endogenous nigro-striatal neurons could be increased, or
(through the expression of extracellular matrix) be usefulin providing a milieu that increases the possibility to re-
form nigro-striatal connectivity (via cell transplantation)
in the adult brain.
Changes in proteins related to dendritic branching
Here we have focused on the increased expression of the
enzyme guanine deaminase (GDA, also known as cypin)
throughout all phases of dopamine denervation of the
striatum, due to its expression profile and the fact that
the protein’s expression has been shown to dramatically
increase dendritic arborisation in the CNS [20,32-35].
Also, guanine deaminase (an enzyme that converts guan-
ine to xanthine) is known to be involved in purine me-
tabolism, the end product of which is urate. Urate, itself,
is thought to be neuroprotective in the ageing brain, as
an increased expression of the protein is suggestive of a
lower risk of Parkinson’s disease [36]. In addition to this,
there is evidence to suggest that purines, released by
dying or injured cells, may induce brain repair via astro-
cytic activity [19].
Here, immunohistochemistry revealed a substantial in-
crease in GDA expression during and after striatal de-
nervation. Such an increase in protein expression could
represent an effort by projection neurons within the stri-
atum to expand their dendritic arbors to facilitate the
formation of new connections from other afferents or
intra-striatal input. With the expression of such proteins
(that may promote the growth of axons and dendrites)
in the striatum after denervation on the rise, and myelin
related proteins being reduced (which may negatively
affect neuronal growth/regeneration) [37], there remains
the real possibility that the denervated striatum is
primed for plasticity. Though this signaling may benefit
efforts at restoring connectivity with the striatum (e.g.,
through cell transplantation), it may greatly complicate
the balance of excitatory and inhibitory input to the dir-
ect and indirect pathway (respectively) that dopamin-
ergic innervation once modulated.
Changes in synaptic functions
The iTRAQ analysis here, indicates that the normal stri-
atum responds to denervation from nigro-striatal neu-
rons by firstly decreasing the expression of synaptic
proteins (Table 1 and Figure 3) followed by an increase
in synapse-related proteins at 7 and 14 days (Tables 2
and 3 and Figure 3). In particular, synaptic vesicle pro-
tein 2B, and synapsin 1 and 2 appear to up-regulated in
response to striatal denervation at 7 and 14 days post
lesioning (Tables 2 and 3). Synapsins have long been
known to regulate synaptic depression and to increase
transmission at synaptic sites [38], and synaptic vesicle
protein 2B (which is associated with high rates of neuro-
transmitter release at the synapse) is known to be absent
from dopaminergic neurons [39]. Such up-regulation of
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that a vast network would have been abolished by lesion-
ing of dopaminergic input, and indicates altered activity
among other striatal afferent projections.
Changes in proteins implicated in Parkinson’s disease
A useful aspect of looking at the proteome of the other-
wise normal mammalian striatum as it is artificially de-
tached from its dopaminergic input (i.e., via 6-OHDA
lesioning of laboratory rats), is that it allows for the
identification of proteins that may be a reaction to the
denervation event alone, and, hence, not part of the aeti-
ology of Parkinson’s disease. For example, iTRAQ ana-
lysis here suggest that NAD-dependent deacetylase
siturin-2 rises (at 3 days post 6-OHDA lesioning) in re-
sponse to dopamine denervation of the striatum
(Table 1). This is interesting when considering that
SIRT1 and SIRT2 have both been implicated in the pro-
tection of neurons against age related disease [40], and
that SIRT2 may enhance alph-synuclein mediated tox-
icity [41]. In addition, NADH dehydrogenase (ubiquin-
one) – an enzyme catalyzing the first step in the
mitochondrial electron transport chain – also appears to
be decreased early on in the striatum in response to 6-
OHDA induced deafferentation from its dopaminergic
input (at 7 days post lesioning; Table 2). Though mito-
chondrial dysfunction has long been linked to oxidative
stress and cell death in PD [42], the data presented here
suggests reduced expression of NADH dehydrogenase in
the striatum is likely to be a response to SNc dopamine
neuron destruction, and not part of the primary cause of
Parkinson’s disease. However, an increase in NADH de-
hydrogenase (ubiquinone) expression after more pro-
longed deafferentation of the striatum (as is suggested
here from the striatal proteome at 14 days post 6-
OHDA lesioning; Table 3) could be of interest due to
the fact that its increased expression may represent a
dramatic rise in the generation of ATP (energy) by cells
within the denervated striatum. This could be important
if there is a process of extensive wound healing and plas-
ticity ongoing in the striatum (as mentioned above). Fi-
nally, the iTRAQ analysis here suggests that there is an
increase in the expression of the voltage-dependent
anion channel 1 (VDAC-1) – a protein identified as link-
ing parkin to defective mitochondria in PD [43,44] –
after complete dopamine deafferentation of the striatum
at 14 days post 6-OHDA lesioning (Table 3). Similarly,
the expression of SEPT5 – which is linked to parkin and
proteosomal degradation [45] - is reduced in the stri-
atum at 3 days post-6-OHDA lesioning (Table 1). Such
findings imply that some of the altered protein expres-
sion in the striatum may be reactionary and not part of
the underlying cause/aetiology of dopamine neuron de-
generation seen in PD.Conclusions
Here, we have detailed changes in the proteome of the
rat striatum as it becomes detached from its dopamin-
ergic input via 6-OHDA lesioning of the medial fore-
brain bundle. This analysis of changing protein
expression in the striatum was conducted over a period
of time when it is known that the striatum loses innerv-
ation from dopaminergic input following 6-OHDA
lesioning [46]. This analysis not only provides a detailed
description of the changing proteome of the striatum
directly related to the destruction of nigro-striatal neu-
rons themselves (e.g., reduced TH and neurofilament ex-
pression), but has also revealed a potential regenerative
growth response (e.g., increased GFAP expression and
GDA/cypin expression) by cells within the target nuclei.
In the future, it will be important to detail the changing
protein profile of the striata of human PD sufferers, as
the time course for degeneration of the circuitry is more
drawn out in the case of human PD and may offer more
details of compensatory changes not seen in the rodent
model. However, comparing the responses of the rat stri-
atum in the 6-OHDA model of PD with the protein ex-
pression seen in human Parkinson’s disease may allow
for the discovery of proteins that the human striata fails
to express when challenged with the loss of nigro-
striatal dopamine neurons, or detail proteins that are
not part of the aetiology of the disease itself (and merely
a response to, or representation of, dopamine cell degen-
eration). In addition, identifying the function of mole-
cules expressed by the otherwise normal striatum to a
denervating event may offer clues to proteins or cellular
pathways that could be manipulated to enhance the sur-
vival and/or connectivity of immature nigro-striatal
dopamine neurons transplanted to Parkinson’s sufferers
as a part of a cell replacement strategy.
Methods
All in vivo procedures were approved by the Animal
Welfare & Ethical Review Body (AWERB) at Keele
University, and were carried out under the licensed au-
thority of the UK Home Office (PPL40/3556). All adult
Sprague Dawley rats were housed in a 12-12 h light–dark
environment, and given free access to food and water
throughout the study.
Medial forebrain bundle 6-OHDA lesioning
Adult, female rats (~230 g in weight) were anesthetised
using isoflurane gas, and subsequently secured in a
stereotaxic frame. With the incisor bar set at −4.5 mm
from horizontal, a midline incision was made along the
scalp and a single small hole drilled in the skull (on the
right side only) 4.0 mm anterior to the bregma suture,
and 1.3 mm lateral to the midline. A fine glass capillary,
filled with a 30 mM 6-OHDA (Sigma)/0.03% ascorbic
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dura, and 3 μl of the solution injected (using a Nanoject
injector; Drummond) into the right medial forebrain
bundle (MFB) over a 3 minute period of time. The nee-
dle was left in situ for an additional 2 minutes, and then
subsequently removed, and the animal sutured and
placed in a warmed cage.
Animals that were either unlesioned (control), or 3 days,
7 days, or 14 days post 6-OHDA injection (lesioning),
were given an overdose of pentobarbitone anesthetic (via
i.p. injection) and cardiac perfused with either 4.0% solu-
tion of paraformaldehyde (PFA) in Tris-buffered saline
(TBS) for histology studies (group 1: n = 4) or ice-cold
sterile 0.9% sodium chloride (saline) for proteomic and
western blot analysis (group 2: n = 4).Tissue / protein extraction
A portion of the striatum (i.e., the central core of the
striatum, cut from a ~500 μm coronal slice through the
basal ganglia at a point where the anterior commissure
lay just ventro-lateral to the lateral ventricles) was dis-
sected and placed in fresh sterile saline. Subsequently,
the saline was aspirated off and the striatal samples
homogenised in 4 volumes (w/v) of 6 M Urea, 2 M thio-
urea, 2% CHAPS and 0.5% SDS using a pellet pestle (30
strokes with the pestle, left on ice for 10 minutes,
followed by another 30 strokes with the pestle). The ex-
tracts were sonicated briefly and left on ice for 10 mi-
nutes, followed by centrifugation at 13,000 x g for
10 minutes at 4°C to pellet any insoluble material. For
mass spectrometry analysis, an aliquot of the extracted
proteins from each rat was precipitated in 6 volumes of
ice-cold acetone overnight at −20°C. The remaining ex-
tracts were stored at −80°C for validation studies. The
acetone precipitates were pelleted by centrifugation at
13,000 x g for 10 minutes at 4°C and the supernatant
was carefully removed and discarded. The pellets were
resuspended in 6 M Urea in 50 mM TEAB. The protein
concentration in each sample was determined using a
Bradford protein assay.Sample preparation for mass spectrometry analysis
Reduction, alkylation and digestion steps were per-
formed using the reagents and according to the recom-
mendations detailed in the iTRAQ labelling kit (AB
Sciex). The extracts were diluted with 50 mM TEAB (so
that the urea concentration was less than 1 M) before
the addition of trypsin and overnight incubation at 37°C.
The digests were then dried down in a vacuum centri-
fuge and iTRAQ labelling carried out according to in-
structions outlined in the iTRAQ labelling kit. The
iTRAQ tags were assigned to samples as follows: 114-
control, 115–3 days, 116–7 days and 117–14 days postlesion. Each tag was incubated with 85 μg of total pro-
tein (as determined by a Bradford protein assay).
iTRAQ-labeled peptides were pooled and made up to
a total volume of 2.4 mls in SCX buffer A (10 mM phos-
phate, pH 3.0 in 20% acetonitrile (Romil, UK)). The
pooled peptides (2.4 mls) were then separated by strong
cation-exchange chromatography (SCX) using a polysul-
foethyl A column, 300A, 5 uM (PolyLC)) at a flow rate
of 400 ul/minute. Following sample injection, the column
was washed with SCX buffer A until the baseline
returned. The gradient was run as follows: 50% SCX
buffer B (10 mM phosphate, 1 M NaCl, pH 3.0 in 20%
acetonitrile) over 25 minutes followed by a ramp up
from 50% to 100% SCX buffer B over 5 minutes. The
column was then washed in 100% SCX buffer B for
5 minutes before equilibrating for 10 minutes with SCX
buffer A. Fractions were collected (400 ul) during the
elution period and dried down completely in a vacuum
centrifuge.
Protein identification and quantification by mass
spectrometry
The iTRAQ tryptic peptide fractions were each resus-
pended in 35 μl of RP buffer A (2% acetonitrile, 0.05%
TFA in water (Sigma Chromasolv plus). Prior to mass
spectrometry analysis, fractions were first separated by
liquid chromatography (Dionex Ultimate 3000) on a
Pepmap C18 column, 75 μm x 15 cm (LC Packings) at a
flow rate of 0.356 μl/minute. Fractions were injected by
full-loop injection (20 μl) and the order of loading was
randomized to minimise effects from carry-over. The el-
uants used were: A. (0.5 TFA in 2% ACN in water) and
B. (0.05% TFA in 90% acetonitrile in water). The gradi-
ent was run as follows: 10 minutes isocratic pre-run at
100% A, followed by a linear gradient from 0-30% B over
100 minutes, followed by another linear gradient from
30%-60% over 35 minutes. The column was then washed
in 100% B for a further 10 minutes, before a final equili-
bration step in 100% A for 10 minutes. During the elu-
tion gradient, fractions were spotted at 10 second
intervals using a Probot (LC Packings) with α-cyano-4-
hydroxycinnamic acid (CHCA) at 3 mg/ml (70% MeCN,
0.1% TFA) at a flow rate of 1.2 μl/min.
Both MS and MS/MS analysis was performed on the
fractionated peptides using an Applied Biosystems 4800
MALDI TOF/TOF mass spectrometer. The mass spec-
trometer was operated under control of 4000 Series Ex-
plorer v3.5.2 software (Applied Biosystems). A total of
1000 shots per MS spectrum (no stop conditions) and
2500 shots per MS/MS spectrum (no stop conditions)
were acquired. The following MS/MS acquisition set-
tings were used: 2KV operating mode with CID on and
precursor mass window resolution set to 300.00
(FWHM). Peak lists of MS and MS/MS spectra were
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the following parameters were used after selective label-
ling of monoisotopic mass peaks: MS peak lists: S/N
threshold 10, Savitzky Golay smoothing (3 points across
peak (FWHM)), no baseline correction, MS/MS peak
lists: S/N threshold 14; smoothing algorithm: Savitzky
Golay, smoothing (7 points across peak (FWHM)).
An automated database search was run using GPS Ex-
plorer v3.6 (AB Sciex). MASCOT was used as the search
engine to search the NCBI non-redundant database
using the following search parameters: precursor ion
mass tolerance of 150 ppm, MS/MS fragment ion mass
tolerance of 0.3 Da, iTRAQ fragment ion mass tolerance
of 0.2 Da, the taxonomy was selected as rats, oxidation
of methionine residues were allowed as variable modifi-
cations and N-term (iTRAQ), lysine (iTRAQ) and
MMTS modification of cysteine residues were set as
fixed modifications. The version of the NCBI database
used was: Tue Oct 04, 2011, and the number of se-
quences in the rat subset was: 19185. Quantification of
the iTRAQ peptides was performed using the GPS Ex-
plorer v3.6 software. The most stringent search settings
were used for protein identification (peptide rank 1 and
total ion score confidence intervals of at least 95%).
iTRAQ Ratios were normalized using the following for-
mula: iTRAQ Ratio = Ratio/(median iTRAQ Ratio of all
found pairs) that was applied in GPS Explorer software.
In order to determine which striatal proteins are chan-
ged in expression levels following 6-OHDA lesioning, all
proteins detected were subjected to strict filtering. Pro-
teins identified from fewer than 3 peptides were deemed
unreliable for quantification, and were excluded from
analysis. Those with an average post-lesion/control ratio
of less than 1.25 or greater than 0.75 were also removed
from the list. Lastly, a statistical analysis of potential sig-
nificant difference between individual peptide iTRAQ
ratios for the remaining 3, 7 and 14 days post-lesion and
unlesioned proteins was determined using a Student’s
pairwise t-test.
In silico protein network analysis
To obtain further insight into potential cellular pathways
that may be modified as a result of protein changes iden-
tified in our experiments, the Ingenuity Pathways Ana-
lysis (IPA) application (Ingenuity Systems) was used as
previously described [47]. IPA dynamically generates
networks of gene, protein, small molecule, drug, and dis-
ease associations on the basis of “hand-curated” data
held in a proprietary database. More than 90% of the in-
formation in this database is “expert-curated” and is
drawn from the full text of peer reviewed journals. Less
than 10% of interactions have been identified by tech-
niques such as natural language processing. In the
current analysis candidate interactions were limited toexperimentally observed interactions only, but could be
drawn from any source in the IPA database. Networks
generated by IPA were limited in this study to ten net-
works comprising a maximum of 35 members per net-
work. To enhance the explorative interpretation of data,
networks are ranked according to a score calculated via
a right tailed Fisher’s exact test. This test outputs a value
that takes into account the original input gene or pro-
teins of interest and the size of the network generated.
Further information on the computational methods im-
plemented in IPA can be obtained from Ingenuity Sys-
tems (http://www.ingenuity.com/).
SDS-polyacrylamide gel electrophoresis and western
blotting
Protein extracts were prepared by boiling in SDS loading
buffer (2% sodium dodecyl sulphate- SDS, 5% 2-
mercaptoethanol, 62.5 mM Tris–HCl, pH 6.8), for
2 min. Proteins were subjected to SDS-PAGE using 12%
polyacrylamide gels and transferred to nitrocellulose
membranes by western blotting. After blocking non-
specific sites with 4% powdered milk solution, mem-
branes were incubated with primary antibodies: 1:3000
mouse anti-TH (tyrosine hydroxylase; Milipore); 1:2000
mouse anti-NFh (neurofilament heavy chain; Sigma);
1:2000 rabbit anti-GFAP (glial fibrillary acidic protein;
Dakko); 1:300 rabbit anti-GAP43 (growth associated
protein 43; Abcam); 1:20000 mouse anti-DARP-32 (Mili-
pore) 1:1000 mouse anti-beta III tubulin (Covance), di-
luted in dilution buffer (PBS, 1% fetal bovine serum, 1%
horse serum and 0.1% BSA). Antibody reacting bands
were visualized by development with either peroxidase-
labeled goat anti-mouse Ig, or peroxidise-labeled swine
anti-rabbit Ig (1 μg/ml in dilution buffer) and a chemilu-
minescent detection system (West Pico, Pierce).
Histology
After removal of the brain specimens, and incubation in
PFA overnight, specimens were transferred to a 30% su-
crose solution in TBS, and allowed to fully sink in the
solution at room temperature (RT). Subsequently, speci-
mens were placed on a sliding, freezing microtome, and
40 μm coronal sections cut through the entire striatum.
Sections were stored in 24-well plates containing TBS
with sodium azide. For immunohistochemistry, sections
were rinsed 3 times in TBS, and incubated in a blocking
solution containing 3% goat serum/TBS for 1 hour at
RT. The blocking solution was subsequently replaced
with one of the following primary antibodies in TBS
containing 1% goat serum, and left to incubate overnight
at RT: a 1:1000 dilution of mouse anti-TH antibody
(tyrosine hydroxylase; Chemicon), 1:500 rabbit anti-
GFAP (glial fibrillary acidic protein; Dakko), or 1:100
rabbit anti GDA (guanine deaminase; Tebu-Bio). The
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followed by a 2 hour incubation in a 1:200 dilution of an
appropriate fluorescent secondary (Molecular Probes).
Subsequently, sections were rinsed 3 times in TBS,
mounted onto slides, and coversliped using Vectashield
Hardmount mounting media (Vector Labs).
Microscopy
Low power images were obtained via the use of a Ham-
mamatsu digital camera attached to a Nikkon Eclipse
80i fluorescence microscope. For detail of fine neuritic
processes, high power images were obtained using a
Leica SP5 confocal microscope imaging system via a 63x
oil emersion objective.
Additional files
Additional files 1: Table S1. A list of all the proteins that were
identified by MALDI TOF/TOF mass spectrometry with total ion score
confidence intervals of greater than 95% and peptide rank of 1. For each
protein identified, the corresponding NCBInr Accession number is shown,
together with the total ion score confidence interval (C.I).% and the
number of peptides used for the identification. iTRAQ ratios, iTRAQ ratio
standard deviation and number of peptides used for the iTRAQ-
quantification are also shown for each protein. Proteins highlighted in
bold font are those that met the significance criteria for inclusion into
the tables in the manuscript (i.e. more than 2 peptides, +/- 1.25x fold
change and a p-vaule of less than 0.05. The iTRAQ tags were assigned as
follows: 114 control (unlesioned), 115 - 3 days-post lesion, 116 - 7 days
post-lesion, 117 - 14 days post-lesion.
Additional files 2: Table S2. A protein – peptide summary of all the
proteins that were identified by MALDI TOF/TOF mass spectrometry with
total ion score confidence intervals of greater than 95% and peptide rank
of 1. For each protein identified (Table S1), the individual peptide
sequences, individual peptide ion score confidence intervals (C.I).% and
individual peptide iTRAQ ratios are given. The iTRAQ tags were assigned
as follows: 114 control (unlesioned), 115 - 3 days-post lesion, 116 - 7 days
post-lesion, 117 - 14 days post-lesion.
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iTRAQ: Isobaric tags for relative and absolute quantification; MALDI
TOF/TOF: Matrix-assisted laser desorption ionisation time-of-flight mass
spectrometry; 6-OHDA: 6-hydroxydopamine; TH: Tyrosine hydroxylase;
DARPP-32: Dopamine and cAMP regulated protein phosphatase 1, regulatory
(inhibitor) subunit 1B; GFAP: Glial fibrillary acidic protein; GDA: Guanine
deaminase; PD: Parkinson’s disease; SNc: Substantia nigra pars compacta;
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NF: Neurofilament polypeptide.
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